Emeryville, California, U.S., November 10, 2026
Metagenomi Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MGX-001, an investigational genome-editing therapy being developed for the treatment of Hemophilia A. The regulatory milestone enables the biotechnology company to advance its lead wholly owned programme into human clinical development through the planned global Phase 1/2 INTEGR8 clinical trial. MGX-001 is designed as a potential one-time treatment that uses targeted genome editing to integrate a functional Factor VIII (FVIII) gene into a specific location within the patient’s genome, with the aim of achieving long-term production of the essential blood-clotting protein. The company expects to initiate the clinical programme in the first half of 2027 and report initial clinical findings during the second half of 2027. The announcement also included Metagenomi’s third-quarter 2026 financial results, reporting $101.7 million in cash, cash equivalents and available-for-sale marketable securities as of September 30, 2026. The development represents an important advancement in genetic medicines and genome-editing research for inherited bleeding disorders.
FDA Clearance Advances MGX-001 into Clinical Development
The FDA’s clearance of the IND application represents a significant regulatory milestone for MGX-001, allowing Metagenomi to begin evaluating the investigational therapy in human participants. The planned INTEGR8 study will be a global, multicenter, open-label, single-arm Phase 1/2 clinical trial involving dose escalation followed by dose expansion. Initial enrolment will focus on adults with moderately severe to severe Hemophilia A. The primary objectives will include evaluating the safety and tolerability of MGX-001 and identifying a suitable dose capable of achieving Factor VIII activity within the normal physiological range. Researchers will also assess the treatment’s biological activity and its potential to provide sustained production of functional FVIII. Metagenomi plans to expand the clinical programme to additional hemophilia treatment centers outside the United States, subject to obtaining the necessary regulatory clearances in other jurisdictions. The company expects to initiate the INTEGR8 trial in the first half of 2027, with initial clinical data covering safety, tolerability and FVIII functional activity anticipated in the second half of the year.
CRISPR Genome Editing Targets Long-Term Factor VIII Production
MGX-001 uses a targeted genome-editing approach designed to deliver durable Factor VIII production following a single treatment. The investigational therapy combines an adeno-associated virus (AAV) vector and a lipid nanoparticle (LNP) delivery system to introduce the genetic components required for editing. The AAV vector delivers a promoterless FVIII gene cassette as donor DNA, while the LNP delivers messenger RNA encoding Metagenomi’s proprietary Type V CRISPR nuclease, MG29-1, together with a guide RNA targeting the albumin gene. The system is designed to integrate the functional FVIII gene into a specific location within an intron of the albumin gene, using the body’s natural albumin promoter to drive production of the clotting protein. This strategy differs from previously approved gene therapies for Hemophilia A that rely on episomal FVIII expression rather than targeted integration into the genome. By using site-specific gene integration, MGX-001 aims to support sustained endogenous Factor VIII production and potentially reduce the need for repeated replacement treatments. Preclinical studies in non-human primates demonstrated Factor VIII activity within the normal physiological range, with dose-dependent responses across the AAV and LNP components. Earlier studies also showed sustained FVIII activity for approximately 19 months. Furthermore, the company reported no detectable off-target genome editing across a series of independent assessment methods. These findings provide the scientific foundation for advancing MGX-001 into clinical testing, although human safety and effectiveness remain to be established.
Advertisement
Metagenomi Reports Third-Quarter 2026 Financial Results
Alongside the regulatory announcement, Metagenomi reported its financial performance for the third quarter ended September 30, 2026. The company reported $101.7 million in cash, cash equivalents and available-for-sale marketable securities, with its anticipated cash runway expected to support operations into 2028. Research and development expenses were $17.5 million for the third quarter of 2026, compared with $25.3 million during the same period in 2025. General and administrative expenses reached $6.9 million, including a one-time net litigation settlement expense of $1.2 million, compared with $6.2 million in the corresponding quarter of the previous year. The company reported a net loss of $21.1 million for the quarter. Metagenomi is also exploring the potential application of its site-specific large gene integration technology in other protein-deficiency disorders. The company believes the same genome-editing approach could potentially support the development of additional genetic medicines targeting conditions involving insufficient production of essential proteins. Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of Metagenomi Therapeutics, highlighted the importance of the FDA clearance and the potential of MGX-001 to provide durable Factor VIII production through targeted genome editing. The latest milestone strengthens Metagenomi’s position in the developing field of CRISPR-based genetic medicines. If future clinical studies demonstrate favorable safety, efficacy and long-term durability, MGX-001 could offer a new treatment approach for people living with Hemophilia A. Further clinical investigation will determine whether the promising preclinical findings translate into meaningful benefits for patients.
Source: Metagenomi Therapeutics press release
